BiotechTube
enGenes Biotech

enGenes Biotech

Vienna, Austria· Est.
engenes.cc
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

enGenes Biotech is a Vienna-based, private biotechnology company that operates as a service provider and technology developer in the biologics manufacturing space. Its core expertise lies in proprietary microbial expression systems, notably its growth-decoupled platform (enGenes-eXpress, eXtra, eXcite), which enables high-titer, secreted protein production and innovative continuous manufacturing processes for plasmid DNA. The company serves clients in biopharma, gene therapy, and industrial biotech by offering tailored development and production services, alongside a small portfolio of purification products like the eXrase endonuclease. Founded from academia, enGenes positions itself as an innovation partner for complex protein and pDNA production challenges.

AntibodiesBiologicsProteomics

Technology Platform

Proprietary growth-decoupled microbial expression systems (enGenes-eXpress, eXtra, eXcite) enabling high-titer, secreted recombinant protein production, and the iCAP platform for continuous, automated plasmid DNA manufacturing.

Opportunities

The booming market for plasmid DNA, driven by mRNA vaccines and gene therapies, presents a major opportunity for enGenes' innovative iCAP continuous production platform.
Furthermore, the biopharma industry's relentless drive for cost reduction and process intensification aligns perfectly with the company's high-yield, secretion-enabled protein expression systems for non-glycosylated therapeutics and enzymes.

Risk Factors

Key risks include the industry's slow adoption of novel, non-GMP manufacturing platforms, requiring significant validation efforts.
The company also faces intense competition from larger, full-service CDMOs and is dependent on protecting its core IP portfolio to maintain its technological edge.

Competitive Landscape

enGenes competes in the crowded contract development and manufacturing (CDMO) and research services space for microbial expression. It differentiates itself through its proprietary secretion and continuous processing technologies, competing against both large, diversified CDMOs and smaller niche players. Its focus on *E. coli* secretion and continuous pDNA production carves out a specific technological niche.

More companies in Biologics / Biosimilars →More companies in Austria →